No label defined (Q31235)
Jump to navigation
Jump to search
No description defined
- COVID-19 vaccination initiation and completion in a multicenter cohort study of insured US transgender and cisgender adults.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
Transgender and gender-diverse (TGD) people may have been disproportionately impacted by the COVID-19 pandemic, yet little is known about vaccination status in this population. (English)
PURPOSE (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
This multicenter cohort study of insured adults examined the rates of COVID-19 vaccine initiation and completion in TGD persons compared to matched cisgender persons. (English)
PURPOSE (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
A cohort of TGD persons and matched cisgender persons enrolled in Kaiser Permanente health plans in Northern and Southern California between 12/1/2020 and 7/31/2021 were analyzed. (English)
METHODS (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
COVID-19 vaccination initiation and completion rates were compared across groups using Cox regression models. (English)
METHODS (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
Among transmasculine persons, the HR (95 % CI) estimates for COVID-19 vaccination initiation and completion were, respectively, 1.35 (1.30-1.40) and 1.78 (1.71-1.85) compared with cisgender women and 1.34 (1.29-1.40) and 1.81 (1.73-1.88) compared with cisgender men. (English)
RESULTS (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
Among transfeminine persons, the corresponding HRs (95 % CIs) for vaccination initiation and completion were 1.35 (1.30-1.40) and 1.78 (1.71-1.85) compared with cisgender women and 1.34 (1.29-1.40) and 1.81 (1.73-1.88) compared with cisgender men. (English)
RESULTS (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
Findings from this cohort of insured adults demonstrated that TGD persons initiated and completed COVID-19 vaccination at higher rates compared to matched cisgender persons. (English)
CONCLUSION (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
Further work is needed to understand vaccination rates and determinants in the broader TGD populations. (English)
CONCLUSION (English)
Copyright © 2024. Published by Elsevier Inc. (English)
2024
Meron (English)
Siira (English)
M
Darios (English)
Getahun (English)
D
Michael J (English)
Silverberg (English)
MJ
Vin (English)
Tangpricha (English)
V
Michael (English)
Goodman (English)
M
Howa (English)
Yeung (English)
H
4 October 2024
16 September 2024
Declaration of Competing Interest The submitted work entitled “A Multi-Center Cohort Study of COVID-19 Vaccination Initiation and Completion in Transgender and Cisgender Adults” has not been previously published, nor is it currently under consideration for publication elsewhere. (English)
This work is supported in part by Contract AD-12–11-4532 from the Patient Centered Outcome Research Institute, Grant R21HD076387 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and Grant R01AG066956 from the National Institute of Aging, and Grants K23 AR075888 and L30 AR076081 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. (English)
There are no conflicts of interests to declare. (English)
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. (English)